GHRS - GH Research PLC
IEX Last Trade
7.1
-0.800 -11.268%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:21:42 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$7.90
-0.80
-10.13%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.50%
1 Month
-22.17%
3 Months
-2.74%
6 Months
-40.67%
1 Year
29.14%
2 Year
-27.28%
Key data
Stock price
$7.10
DAY RANGE
$7.14 - $7.90
52 WEEK RANGE
$5.47 - $14.99
52 WEEK CHANGE
$28.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Theis Terwey
Region: US
Website: ghres.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ghres.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD)
Recent news